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Objectives This subanalysis of the TNT (Treating to New Targets) study investigates the effects of intensive lipid lowering with
atorvastatin in patients with coronary heart disease (CHD) with and without pre-existing chronic kidney disease (CKD).
Background Cardiovascular disease is a major cause of morbidity and mortality in patients with CKD.
Methods A total of 10,001 patients with CHD were randomized to double-blind therapy with atorvastatin 80 mg/day or 10
mg/day. Patients with CKD were identified at baseline on the basis of an estimated glomerular filtration rate
(eGFR) 60 ml/min/1.73 m2 using the Modification of Diet in Renal Disease equation. The primary efficacy out-
come was time to first major cardiovascular event.
Results Of 9,656 patients with complete renal data, 3,107 had CKD at baseline and demonstrated greater cardiovascu-
lar comorbidity than those with normal eGFR (n  6,549). After a median follow-up of 5.0 years, 351 patients
with CKD (11.3%) experienced a major cardiovascular event, compared with 561 patients with normal eGFR
(8.6%) (hazard ratio [HR]  1.35; 95% confidence interval [CI] 1.18 to 1.54; p  0.0001). Compared with ator-
vastatin 10 mg, atorvastatin 80 mg reduced the relative risk of major cardiovascular events by 32% in patients
with CKD (HR  0.68; 95% CI 0.55 to 0.84; p  0.0003) and 15% in patients with normal eGFR (HR  0.85;
95% CI 0.72 to 1.00; p  0.049). Both doses of atorvastatin were well tolerated in patients with CKD.
Conclusions Aggressive lipid lowering with atorvastatin 80 mg was both safe and effective in reducing the excess of cardiovascular
events in a high-risk population with CKD and CHD. (Treating to New Targets Study; NCT00327691) (J Am Coll Car-
diol 2008;51:1448–54) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.072w
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sncreased cardiovascular mortality and morbidity risk in pa-
ients with advanced chronic kidney disease (CKD) is well
stablished (1,2), and even mild to moderate CKD is associ-
ted with an increased incidence of cardiovascular events (3,4).
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April 15, 2008:1448–54 High-Dose Atorvastatin in CKDimited the use of statins in the CKD population (5).
espite under-representation of patients with mild to
oderate CKD in major statin trials (6), data suggest
7,8) that lower doses of statins in CKD patients are
ffective in preventing cardiovascular events. However, it
emains unclear whether CKD patients benefit from aggressive
ipid lowering with statins in the same manner as patients with
ormal renal function.
Unlike some previous long-term statin trials, the TNT
Treating to New Targets) study (9) did not exclude
atients on the basis of serum creatinine levels. The
urrent post-hoc analysis of the TNT study was under-
aken to identify and clinically characterize a patient
ohort presenting with coronary heart disease (CHD)
nd mild to moderate CKD and to investigate the effect
f intensive lipid lowering with atorvastatin 80 mg on the
isk of future cardiovascular events.
ethods
he design of the TNT study has been described in detail
reviously (9).
atient population. Eligible patients were men and women
ges 35 to 75 years with clinically evident CHD, defined as
revious myocardial infarction, previous or current angina
ith objective evidence of atherosclerotic CHD, or a history
Figure 1 Screening, Enrollment, and Outcomes in Patients Wit
eGFR  estimated glomerular filtration rate.f coronary revascularization.
xclusion criteria have been de-
cribed previously (9).
tudy design. Any previously
rescribed lipid-regulating drugs
ere discontinued at screening,
nd all patients required a wash-
ut period of 1 to 8 weeks. Pa-
ients with low-density lipopro-
ein cholesterol (LDL-C) levels
etween 130 and 250 mg/dl and
riglyceride levels600 mg/dl en-
ered an 8-week run-in period of
pen-label treatment with atorva-
tatin 10 mg/day. At the end of
he run-in phase (baseline), pa-
ients with a mean LDL-C130 mg/dl (determined 4 weeks
nd 2 weeks before randomization) were randomized to
ouble-blind therapy with either 80 mg/day or 10 mg/day of
torvastatin for up to 6 years (Fig. 1).
fficacy and safety outcomes. The primary efficacy out-
ome was the occurrence of a major cardiovascular event,
efined as death from CHD, nonfatal nonprocedure-related
yocardial infarction, resuscitation after cardiac arrest, or
atal or nonfatal stroke.
onic Kidney Disease and Patients With Normal eGFR
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
CKD  chronic kidney
disease
eGFR  estimated
glomerular filtration rate
HR  hazard ratio
LDL-C  low-density
lipoprotein cholesterol
MDRD  Modification of
Diet in Renal Diseaseh Chr
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High-Dose Atorvastatin in CKD April 15, 2008:1448–54As recommended by the American Heart Association
nd National Kidney Foundation (10,11), renal function
as assessed using the Modification of Diet in Renal
isease (MDRD) equation (12), a serum creatinine-based
stimate of glomerular filtration rate (eGFR), as described
reviously (13). Patients with eGFR 60 ml/min/1.73 m2
t baseline were classified as having CKD; patients with
GFR 60 ml/min/1.73 m2 were classified as having
ormal or near-normal renal function.
tatistical analyses. The primary analysis of efficacy in
he TNT study was the difference between the atorvasta-
in 80 and 10 mg treatment groups for time to first
ccurrence of a major cardiovascular event during the
-year follow-up period, based on log-rank analyses.
azard ratios (HRs) and their 95% confidence intervals
CIs) were also calculated using the Cox regression
odel. Relative risk reductions based on the HRs were
eported, as well as absolute risk reductions based on
vent incidence. Two-sided p values 0.05 were regarded
s significant. All analyses were performed on an
ntention-to-treat basis.
aseline Demographics and Clinical Characteristics of Patients Wi
Table 1 Baseline Demographics and Clinical Characteristics of
Baseline Characteristic
(at Randomization)
Patients With CKD
Atorvastatin 10 mg
(n  1,505)
Atorvastatin 80 mg
(n  1,602)
Men 992 (65.9) 1,110 (69.3)
Age, yrs 65.6  6.9 65.5  7.1
65 880 (58.5) 956 (59.7)
Race
White 1,439 (95.6) 1,519 (94.8)
Black 26 (1.7) 25 (1.6)
Other 40 (2.7) 58 (3.6)
Body mass index, kg/m2 28.7  4.7 28.3  4.4
Current smoker 130 (8.6) 150 (9.4)
eGFR, ml/min/1.73 m2 52.8  6.6 53.0  6.4
Lipids, mg/dl
LDL cholesterol 96.5  17.5 96.3  17.5
Total cholesterol 175.9  24.4 175.9  24.4
Triglycerides 159.8  71.9 159.2  72.4
HDL cholesterol 47.6  11.2 48.0  11.5
Blood pressure, mm Hg
Systolic 133.3  17.7 132.8  17.8
Diastolic 77.5  9.8 77.4  9.8
Cardiovascular history
Angina 1,234 (82.0) 1,305 (81.5)
Myocardial infarction 836 (55.5) 949 (59.2)
Hypertension 944 (62.7) 1,005 (62.7)
Metabolic syndrome 925 (61.5) 973 (60.7)
Coronary artery bypass graft 824 (54.8) 844 (52.7)
Coronary angioplasty 759 (50.4) 807 (50.4)
Arrhythmia 306 (20.3) 350 (21.8)
Diabetes 273 (18.1) 273 (17.0)
Peripheral artery disease 239 (15.9) 268 (16.7)
Congestive heart failure 198 (13.2) 180 (11.2)
Cerebrovascular accident 123 (8.2) 103 (6.4)alues are number of patients (%) or mean  SD.
CKD  chronic kidney disease; eGFR  estimated glomerular filtration rate; HDL  high-density lipopresults
f a total of 10,001 patients randomized, 9,656 (4,827
eceiving atorvastatin 80 mg and 4,829 receiving atorvasta-
in 10 mg) had complete renal data and were included in the
urrent analysis (Fig. 1). At baseline, 3,107 patients had
KD, of whom 3,078 had stage 3 CKD (eGFR 30 to 59
l/min/1.73 m2) and 29 had stage 4 CKD (eGFR 15 to 29
l/min/1.73 m2). Patients with CKD were older, and there
ere more women and fewer smokers than among patients
ith normal eGFR (Table 1). Pre-existing cardiovascular
orbidity at baseline was generally greater in patients with
KD than in patients with normal eGFR (Table 1).
espite characteristic differences at baseline between pa-
ients with CKD and patients with normal eGFR, there was
o imbalance by randomized treatment assignment (Table 1).
edian follow-up was 5.0 years after randomization in both
GFR groups.
erum lipid levels. Baseline lipid levels (following 8 weeks’
pen-label atorvastatin 10 mg) were generally well matched
etween patients with CKD and patients with normal
D and Patients With Normal eGFR by Treatment
nts With CKD and Patients With Normal eGFR by Treatment
Patients With Normal eGFR
All
 3,107)
Atorvastatin 10 mg
(n  3,324)
Atorvastatin 80 mg
(n  3,225)
All
(n  6,549)
102 (67.7) 2,917 (87.8) 2,816 (87.3) 5,733 (87.5)
5.5  7.0 58.7  8.8 59.1  8.7 58.9  8.8
836 (59.1) 923 (27.8) 926 (28.7) 1,849 (28.2)
958 (95.2) 3,108 (93.5) 3,028 (93.9) 6,136 (93.7)
51 (1.6) 118 (3.5) 101 (3.1) 219 (3.3)
98 (3.2) 98 (2.9) 96 (3.0) 194 (3.0)
8.5  4.5 28.6  4.6 28.4  4.5 28.5  4.5
280 (9.0) 510 (15.3) 478 (14.8) 988 (15.1)
2.9  6.5 71.4  7.9 71.0  7.8 71.2  7.8
6.4  17.5 98.1  17.5 97.7  17.4 97.9  17.5
5.9  24.4 174.0  23.5 174.0  23.3 174.0  23.4
9.5  72.2 145.5  70.3 145.8  67.7 145.7  69.0
7.8  11.4 47.0  10.6 47.3  10.9 47.1  10.7
3.0  17.7 129.7  16.3 129.5  15.9 129.6  16.1
7.5  9.8 78.4  9.3 78.0  9.2 78.2  9.3
539 (81.7) 2,684 (80.7) 2,655 (82.3) 5,339 (81.5)
785 (57.5) 1,954 (58.8) 1,882 (58.4) 3,836 (58.6)
949 (62.7) 1,678 (50.5) 1,594 (49.4) 3,272 (50.0)
898 (61.1) 1,788 (53.8) 1,697 (52.6) 3,485 (53.2)
668 (53.7) 1,428 (43.0) 1,388 (43.0) 2,816 (43.0)
566 (50.4) 1,875 (56.4) 1,791 (55.5) 3,666 (56.0)
656 (21.1) 587 (17.7) 525 (16.3) 1,112 (17.0)
546 (17.6) 441 (13.3) 444 (13.8) 885 (13.5)
507 (16.3) 303 (9.1) 316 (9.8) 619 (9.5)
378 (12.2) 183 (5.5) 174 (5.4) 357 (5.5)
226 (7.3) 128 (3.9) 138 (4.3) 266 (4.1)th CK
Patie
(n
2,
6
1,
2,
2
5
9
17
15
4
13
7
2,
1,
1,
1,
1,
1,otein; LDL  low-density lipoprotein.
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April 15, 2008:1448–54 High-Dose Atorvastatin in CKDGFR (Table 1). Patients with CKD had a higher triglyc-
ride level at baseline than patients with normal eGFR
159.5 mg/dl vs. 145.7 mg/dl); however, atorvastatin 80 mg
owered triglycerides to a similar level in patients with CKD
139.0 mg/dl) and patients with normal eGFR (134.2
g/dl) compared with atorvastatin 10 mg (167.6 and 154.9
g/dl, respectively). Mean LDL-C levels attained at the final
isit with atorvastatin 80 mg versus atorvastatin 10 mg were
imilar for patients with CKD (79.0 mg/dl vs. 99.0 mg/dl) and
ith normal eGFR (80.0 mg/dl vs. 102 mg/dl). High-density
ipoprotein cholesterol levels remained stable during the study,
ith no differences between treatment groups.
lood pressure. Systolic blood pressure at baseline was
lightly higher in patients with CKD than in patients with
ormal eGFR (Table 1). There was little change in systolic
nd diastolic blood pressure over the course of the study,
ith no significant differences observed between random-
zed treatment groups. There was a greater use of inhibitors
f the renin-angiotensin system during the trial in patients
ith CKD (64.8% of patients receiving atorvastatin 80 mg
nd 66.0% of patients receiving atorvastatin 10 mg) than in
atients with normal eGFR (56.5% and 59.4%, respectively).
ardiovascular outcomes. After a median follow-up of
.0 years, irrespective of treatment assignment, 351 patients
ith CKD (11.3%) experienced a first major cardiovascular
vent compared to 561 patients with normal eGFR at
aseline (8.6%). Thus, patients with CKD were at a signifi-
antly greater risk than patients with normal renal function
HR 1.35; 95% CI 1.18 to 1.54; p  0.0001). In patients
ith CKD at baseline, a first major cardiovascular event was
xperienced by 149 patients (9.3%) receiving atorvastatin 80
g and 202 patients (13.4%) receiving atorvastatin 10 mg,
32% relative reduction in risk with intensive lipid lowering
HR 0.68; 95% CI 0.55 to 0.84; p  0.0003) (Fig. 2). The
bsolute risk reduction in patients with CKD was substan-
ial (4.1%), yielding a number needed to treat of 24 to
revent 1 major cardiovascular event over 5 years. In
atients with normal eGFR at baseline, a smaller but
ignificant 15% relative reduction in risk of major cardio-
ascular events was observed with atorvastatin 80 mg (7.9%)
ersus atorvastatin 10 mg (9.2%) (HR 0.85; 95% CI 0.72 to
.00; p  0.049; number needed to treat  74) (Fig. 2).
For all predefined secondary end points, event rates were
igher in CKD patients than in patients with normal
GFR. In patients with CKD, treatment with atorvastatin
0 mg resulted in significant reductions in the risk of the
econdary outcomes any cardiovascular event (HR 0.76;
5% CI 0.67 to 0.86), major coronary event (HR 0.65; 95%
I 0.51 to 0.83), any coronary event (HR 0.75; 95% CI 0.65
o 0.86), cerebrovascular event (HR 0.66; 95% CI 0.49 to
.89), and congestive heart failure with hospitalization (HR
.54; 95% CI 0.38 to 0.77) compared with atorvastatin 10
g (Fig. 3). We observed a significantly greater treatment
ffect in patients with CKD than in patients with normal
GFR for major coronary events and hospitalization for rongestive heart failure. Otherwise, there was no significant
eterogeneity of treatment effect between patients with
KD and patients with normal eGFR for primary or
econdary outcomes.
afety. Safety of atorvastatin 80 mg in patients with CKD
as similar to that reported for the overall TNT population
9), with no unexpected safety concerns identified. Rates of
reatment-related adverse events and discontinuations due
o treatment-related adverse events were similar between
atients with CKD and patients with normal eGFR for each
reatment group (Table 2). Incidences of hematuria and
lbuminuria were similar between patients with CKD and
atients with normal eGFR for each treatment group (Table
). There were no reports of serious adverse events associated
ith these urinary abnormalities in either treatment group.
iscussion
his post-hoc analysis of the TNT study extends the
ardiovascular benefit of aggressively lowering LDL-C to a
igh-risk patient population with mild to moderate CKD
nd stable CHD. The absolute and relative reductions in
ardiovascular events with an aggressive atorvastatin treatment
trategy appear to be greater in CHD patients with mild to
oderate CKD than in those with normal or near-normal
Figure 2 Time to First Major CV Event by Treatment in Patients
With CKD and With Normal eGFR at Baseline
In patients with chronic kidney disease (CKD) at baseline, intensive lipid lower-
ing with atorvastatin 80 mg resulted in a 32% relative reduction in risk of major
cardiovascular (CV) events compared with atorvastatin 10 mg (p  0.0003). In
patients with normal or near-normal estimated glomerular filtration rate (eGFR)
at baseline, a smaller but significant 15% relative reduction in risk of major CV
events was observed with atorvastatin 80 mg (p  0.049). ARR  absolute
risk reduction; CI  confidence interval; HR  hazard ratio; NNT  number
needed to treat.enal function.
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High-Dose Atorvastatin in CKD April 15, 2008:1448–54enal insufficiency and cardiovascular disease. The re-
ults of the TNT study are consistent with other observa-
ions that renal function is an important independent
redictor of cardiovascular disease (1–4). At entry to the
ouble-blind phase of the study, CKD patients had a
reater prevalence of cardiovascular risk factors, existing
ardiovascular disease, and target organ damage. In addi-
ion, over the 5 years of follow-up, patients with CKD had
significantly greater risk of a major cardiovascular event
han patients with normal or near-normal renal function.
Atorvastatin 80 mg significantly reduced the incidence of
ajor cardiovascular events compared to atorvastatin 10 mg
n patients with CKD and patients with normal or near-
ormal renal function at baseline. The 32% relative risk
eduction in patients with CKD was quantitatively larger
han the 15% relative risk reduction in patients with normal
GFR and may be related to the higher cardiovascular risk
nd disease burden in patients with CKD. A significant
ose-dependent improvement in renal function for atorva-
tatin 80 mg versus atorvastatin 10 mg has been reported in
his patient cohort (13) and may have contributed to the
elatively high beneficial effect on cardiovascular outcomes
n the patients with CKD. The increased risk associated
ith CKD was greatly reduced but not completely elimi-
ated in CKD patients treated with 80 mg of atorvastatin,
Figure 3 Primary and Secondary Event Rates in Patients With
For all predefined secondary end points, event rates were higher in CKD patien
statin 80 mg resulted in significant reductions, compared with atorvastatin 10
major coronary event, any coronary event, cerebrovascular event, and congesti
(includes 345 patients without complete renal data). TNT  Treating to New Tahose cardiovascular risk fell to a level near that in patients aith normal eGFR who received lower-dose atorvastatin.
his relative risk reduction with aggressive statin therapy in
NT was substantially greater than that observed previously
ith a less intensive statin regimen (8).
Almost one-third of TNT participants had stage 3
KD (based on eGFR 30 to 59 ml/min/1.73 m2), similar
o the CKD rate estimate in patients with cardiovascular
isease from NHANES 1999 to 2004 (14). The underuse
f statins in patients with CKD may, in part, be attrib-
table to the failure to recognize the heightened cardio-
ascular risk associated with the early stages of CKD.
hus, the routine use of the MDRD equation appears to
e a useful screening tool for patients with CHD to
dentify a very high-risk subset with CKD who can
enefit from intensive lipid lowering.
Patients with mild to moderate CKD and CHD may
iffer from those with more advanced renal failure or
nd-stage renal disease. Data from the German Diabetes
nd Dialysis Study showed limited benefit with moderate-
ose atorvastatin in a group of diabetic patients with
ong-standing end-stage renal disease (15). Our observa-
ions in this study of diabetic and nondiabetic patients
ith CHD provide support for the current suggested
valuation and screening strategies, as well as treatment
uidelines recommended by the American Heart Associ-
and Patients With Normal eGFR
n in patients with normal eGFR. In patients with CKD, treatment with atorva-
the risk of the following secondary outcomes: any cardiovascular event,
rt failure with hospitalization. *All patients randomized in the TNT study
study; other abbreviations as in Figure 2.CKD
ts tha
mg, in
ve hea
rgetstion and the National Kidney Foundation (11).
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April 15, 2008:1448–54 High-Dose Atorvastatin in CKDipid-lowering recommendations. Recent recommenda-
ions of the National Lipid Association Statin Safety As-
essment Task Force (16) indicate that CKD should not
reclude use of a statin. Underuse of statins in patients with
KD may relate to concerns over potential toxicity in
atients with reduced renal clearance. Atorvastatin, in con-
rast to many other statins, does not require dosage modi-
cation at any level of renal function (17). The significant
ardiovascular benefits of atorvastatin 80 mg/day in patients
ith CHD and CKD were achieved without additional
afety concerns or increased risk, consistent with other data
hat have shown high-dose atorvastatin to be safe and well
olerated (18). Specifically, there was no increase in serious
enal adverse events or events with potential for renal
omplications.
tudy limitations. Our study has several limitations, in-
luding the absence of an untreated control group. All
atients received either 80 mg or 10 mg of atorvastatin
uring the double-blind phase of the study to comply with
xisting CHD guidelines. In addition, despite being evalu-
ted for accuracy in clinical studies, the MDRD estimate of
lomerular filtration rate used in the current analysis re-
ains an estimate, and categorization of patients as having
KD or a normal glomerular filtration rate is subject to the
imitations of the formula. Classification of CKD based on
single creatinine measurement is not ideal, but in this large
tudy was unlikely to lead to any systematic bias. General-
zations of TNT data to other CKD populations without
HD should be made with caution because the cause(s) of
KD in the TNT population are unknown. Conclusions
egarding patients with more advanced renal dysfunction are
imited, given the small proportion of advanced CKD
atients in this analysis.
onclusions
ata from this TNT subanalysis demonstrate that mild to
oderate CKD is an important comorbidity that increases
ardiovascular risk in patients with CHD. Our observations
elected Safety Outcomes in Patients With CKD and Patients With
Table 2 Selected Safety Outcomes in Patients With CKD and P
Atorvastati
(n  1,
Treatment-related adverse events 78 (5
Discontinuations attributable to treatment-related adverse events 29 (1
Hematuria 51 (3
Albuminuria 25 (1
Persistent elevations in alanine aminotransferase and/or
aspartate aminotransferase*
1 (0
Persistent elevations in creatine phosphokinase† 0
Two measurements 3 times the upper limit of normal, obtained 4 to 10 days apart; †2 measu
Abbreviations as in Table 1.upport the current guidelines (19) that advocate the use ofigh-dose statin therapy to achieve lower target LDL-C
evels for optimal prevention of cardiovascular events in
igh-risk patient groups.
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